<DOC>
	<DOCNO>NCT00100815</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine capecitabine , work different way stop growth tumor cell , either kill cell stop dividing . Bevacizumab may stop growth tumor cell stop blood flow tumor . Giving gemcitabine capecitabine together bevacizumab may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine capecitabine together bevacizumab work treat patient metastatic unresectable pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine , Capecitabine , Bevacizumab Treating Patients With Metastatic Unresectable Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine progression-free survival patient metastatic unresectable adenocarcinoma pancreas treat gemcitabine , capecitabine , bevacizumab . Secondary - Determine clinical response patient treat regimen . - Determine toxicity regimen patient . - Determine quality life patient treat regimen . OUTLINE : This open-label , multicenter study . Patients receive bevacizumab IV 30-90 minute day 1 , oral capecitabine twice daily day 1-14 , gemcitabine IV 30 minute day 1 8 . Courses repeat every 21 day 12 month absence disease progression unacceptable toxicity . Quality life assess baseline weekly 3 week . Patients follow every 2-4 month 1 year every 6 month least 5 year . PROJECTED ACCRUAL : A total 35 patient accrue study within 8.8-17.5 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma pancreas meet 1 follow criterion : Newly diagnose previously treat metastatic disease Unresectable disease No CNS brain metastasis PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 01 Life expectancy More 3 month Hematopoietic Absolute neutrophil count &gt; 1,500/mm^3 WBC &gt; 3,000/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin â‰¥ 9 g/dL ( transfusion epoetin alfa allow ) No evidence bleed diathesis coagulopathy Hepatic Bilirubin &lt; 2 mg/dL AST ALT &lt; 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) INR &lt; 1.5 ( except patient receive fulldose warfarin ) Renal Creatinine &lt; 1.5 mg/dL No proteinuria OR Urine protein &lt; 500 mg 24hour urine collection No clinically significant impairment renal function Cardiovascular No uncontrolled hypertension ( blood pressure &gt; 160/110 mm Hg medication ) No New York Heart Association class IIIV congestive heart failure No unstable symptomatic arrhythmia require medication Chronic atrial arrhythmia ( i.e. , atrial fibrillation paroxysmal supraventricular tachycardia ) allow No clinically significant grade IIIV peripheral vascular disease No arterial thromboembolic event within past 6 month , include follow : Transient ischemic attack Cerebrovascular accident Unstable angina Myocardial infarction Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious systemic disease No significant traumatic injury within past 28 day No serious nonhealing wound , ulcer , bone fracture No history disease , metabolic dysfunction , physical examination finding , clinical laboratory find would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery More 28 day since prior major surgery open biopsy More 7 day since prior fine needle aspiration core biopsy No concurrent major surgery Other More 4 week since prior concurrent participation experimental drug study More 12 month since prior adjuvant therapy No prior systemic therapy metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>